Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with confirmed diagnosis of unresectable HCC
Physician-initiated decision to treat with regorafenib (prior to study enrollment)
You may not be if
Participation in an investigational program with interventions outside of routine clinical practice
Past treatment with regorafenib
Clareo Health | Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
